DOCSLIB.ORG

Aus. & N.Z. Dialysis and Transplant Survey

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aus. & N.Z. Dialysis and Transplant Survey THIS SECTION FOR ALL PATIENTS DIALYSED AT ANY TIME DURING THIS SURVEY See instructions on the back of the form AUS. & N.Z. DIALYSIS AND TRANSPLANT SURVEY PERIOD THIS SECTION FOR ALL PATIENTS 19 TYPE OF 20 DRY WEIGHT 21 UNCORRECTED 22 PHOSPHATE 23 HAEMOGLOBIN 24 EPO AGENT 25 FERRITIN 26 % SATURATION IRON DIALYSIS AT LAST DX CALCIUM (Transferrin Saturation) REGISTRY NUMBER INITIAL HOSPITAL CURRENT PARENT HOSPITAL g/l ug/l Hospital / State Hospital Unit No. Hospital / State Hospital Unit No. Physician kg mmol/l mmol/l (see list) HD and PD Patients Last Available Y=Yes N=No Within last 3 months of Survey or record not done 3 DATE OF BIRTH 4 GENDER HAEMODIALYSIS Surname Given Names 27 DIALYSER BRAND (Write In) 28 BLOOD 29 SESSIONS 30 HOURS 31 UREA REDUCTION or Kt/V FLOW RATE PER WEEK PER SESSION CODE BRAND NAME AND MODEL Method Value 6 PRIMARY RENAL DISEASE (Record from list) 7 BIOPSY 8 SE.CREATININE 5 ETHNICITY (Record from list) Pump Speed OTHER - OTHER - Y / N mls/min See List 9 COUNTRY OF BIRTH (If Australia or NZ - Tick box) 10 POSTCODE AT ENTRY POSTCODE AT END SURVEY 32 ACCESS IN USE (Functioning only) AUST NZ OTHER COUNTRY (Please specify) AT FIRST HD 1-Native AT LAST HD 2=Synthetic PLEASE COMPLETE SECTIONS 19-58 INCLUSIVE, ACCORDING TO THE TREATMENT 11 CO-MORBID CONDITIONS AT ENTRY 3=Tunnel CV Catheter UNDERTAKEN BY THE PATIENT. COMPLETE ALL RELEVANT SECTIONS IN THE EVENT OF 4=Non Tunnel CV THE PATIENT HAVING MORE THAN ONE TREATMENT IN THE SURVEY PERIOD. LATE REFERRAL HEIGHT (cms) WEIGHT (kg) CIGARETTE SMOKING Catheter Once only entry <3 MONTHS BEFORE N=Never ALL PERITONEAL DIALYSIS FIRST TREATMENT F=Former (Y/N) C=Current 33 PET TEST (Once only) 34 CONNECTION SYSTEM 35 PERITONITIS 36 NUMBER OF EPISODES OF 37 TOTAL VOLUME OF Within first 6 mths CODE (Write In) DATE OF FIRST EPISODE PERITONITIS DURING SURVEY WEEKLY EXCHANGES DIABETES DISEASE AT ENTRY AND DURING CURRENT SURVEY N=No Dx/Plasma Creatinine O=Type 1 - Insulin dependent DM at 4 hours Y=Yes N=No CHRONIC CORONARY PERIPHERAL CEREBRO P=Type 2 - Non-Insulin requiring DM S=Suspected LUNG (Y/S/N) ARTERY (Y/S/N) VASCULAR (Y/S/N) VASCULAR (Y/S/N) Q=Type 2 - Insulin requiring DM 38 CREATININE CLEARANCE 39 DIALYSATE ONLY 40 RESIDUAL RENAL FUNCTION 41 PD SOLUTIONS - Y=Yes N=No (Creatinine Clearance) (Please fill in all boxes) AT ENTRY Dialysate ONLY WEEKLY Kt/V LAST Adjusted for Body Adjusted for body Other Surface Area Surface Area CURRENT Litres/week/1.73m² Range 0.1 - 5.0 Litres/week/1.73m² Glucose Icodextrin Low GDP *** *** *** *** *** Range 10-200 Litres/Week OTHER CO-MORBID CONDITIONS (Write in) AT ENTRY OR CURRENT GRAFT (IN THE EVENT OF BOTH GRAFT FAILURE AND RETRANSPLANT IN THIS SURVEY - USE A NEW FORM) PREVIOUS SURVEYS 42 GRAFT 43 DATE OF THIS 44 REFERRING 45 DONOR 46 TRANSPLANT 47 RECIPIENT ANTIBODY 48 NUMBER OF REJECTION NUMBER TRANSPLANT HOSPITAL HOSPITAL HOSPITAL STATUS AT GRAFT EPISODES THIS SURVEY CURRENT CMV EBV (Complete acute rejection 12 CENTRE OF TREATMENT HOSPITAL / CENTRE NAME (Write in or tick if same) CENTRE CODE DATE TRANSFER 1=Positive 2=Negative form for each episode at Enter geographical CURRENT 3=Not done any time during the location at Death or End survey) of Survey LAST 49 DONOR DETAILS 50 TOTAL 51 IMMEDIATE 52 DISEASE IN 53 DATE FIRST PROVEN 54 GRAFT FAILURE Serum Creatinine SOURCE AGE SEX ISCHAEMIA FUNCTION GRAFT (eg. Graft biopsy) Cause (Record from list) at Graft Failure OTHER - 14 HEPATITIS C ANTIBODY (Hours) (See list) (See list) REASON FOR DIALYSIS MODALITY CHANGE from - 1=Positive CURRENT LAST 55 MONOCLONAL / POLYCLONAL THERAPY (Record from list) CAPD to APD / APD to CAPD / Any PD to HD / HD to any PD 2=Negative Enter Reason for Change FROM Previous Modality TO Current Modality - Refer to codes on back of form 3=Not done COURSE DATE AGENT OTHER NO OF DOSES GIVEN REASON OTHER 13 COURSE OF TREATMENT SEQ SEQ SEQ 1st No No No COMPLETE ACCORDING TO CODE CODE DAY MTH YR REASON CODE DAY MTH YR REASON CODE DAY MTH YR REASON E APD / IPD 1 16 31 M CAPD 2 17 32 56 TOTAL DAILY DRUG DOSE (mg) BC HD Hospital-Conventional 3 18 33 TOTAL INITIAL DC HD Satellite-Conventional ORAL DOSE 1 Mth 2 Mth 3 Mth 6 Mth 1 Yr 2 Yr 3 Yr 5 Yr 7 Yr 10 Yr 15 Yr 20 Yr 25 Yr 30 Yr 35 Yr 40 Yr 45 Yr 50 Yr FC HD Home-Conventional 4 19 34 BQ HD Hospital-Quotidian AZA DQ HD Satellite-Quotidian 5 20 35 CYA FQ HD Home-Quotidian 6 21 36 PRED G Transplant in AUST/NZ MMF H Date of last post graft dialysis 7 22 37 X Transplant Overseas MPA 8 23 38 T Graft function ceased - Temporary SIROL P Graft function ceased - Permanent 9 24 39 TACROL J Own kidney function recovered. 10 25 40 Dialysis ceased K Date of last visit if lost to 11 26 41 follow up 12 27 42 Z Date of Death 57 BODY WEIGHT (kg) 13 28 43 14 29 44 58 SERUM CREATININE 15 30 45 (umol/L) 15 CANCER EVER? (Y/N) 16 CAUSE OF DEATH (Record from list) 17 WAS GRAFT SUSTAINING LIFE? 18 PARENTHOOD DATE OF LAST OUTCOME If Yes, enter separate Without dialysis at time of Has this patient become pregnant or Y=Yes If Yes, please complete the Pregnancy Cancer Form death Y=Yes N=No fathered a child during this survey N=No Outcome form 5 - ETHNICITY PRIMARY RENAL DISEASE Continued... CAUSE OF DEATH continued... 33 - PET TEST (Required once only per patient) 52 - DISEASE IN GRAFT (Histologically proven) 0000 Response Unidentifiable 007 Cortical Necrosis Standard Peritoneal Dialysis Equilibration Test Complete this section for FUNCTIONING or FAILED GRAFTS 0001 Not Stated performed 1-6 months after initiation of PD. (2.5% 2 008 Interstitial Nephritis INFECTION B BK Virus Nephropathy in Graft 1101 Oceanian - Australian litre exchanges) 009 Congenital Renal Hypoplasia and Dysplasia Please enter code for nature of infective organism, Y Disease Recurrence - Primary Renal Disease and Disease in 1102 Oceanian - Australian Aboriginal Provide dialysis/plasma creatinine at 4 hours. 010 Loss of Single Kidney (Trauma-Surgery) after the code for site of infection. Please specify Range 0.1-1.2 Graft the same 1103 Oceanian - Australian South Sea Islander 011 Megaureter type of organism. eg. Staph, CMV, Candida, etc. D De Novo Glomerulonephritis - Primary Renal Disease Known 1104 Oceanian - Torres Strait Islander 012 Oxalosis e.g. 321 Lung infection - bacterial (staph) and not the Same 38 - 40 - PD CLEARANCE STUDIES 1201 Oceanian - New Zealand Maori 013 Cystinosis 322 Lung infection - viral (CMV) G Glomerulonephritis in Graft - Primary Renal Disease Generated from a 24 hour collection of PD effluent 1202 Oceanian - New Zealand European 014 Balkan Nephropathy 31 CNS 1 Bacterial Unknown or Not Biopsied 32 Lung 2 Viral and urine. 1300 Oceanian - Melanesian And Papuan (Specify) 015 Renal Cell Carcinoma (GRAWITZ) In cases of glomerulonephritis, where histological confirmation of 33 Urinary tract 3 Fungal NOTE: Dialysate Creatinine Clearances and Kt/V both 1400 Oceanian - Micronesian (Specify) 016 Transitional Cell Carcinoma Urinary Tract recurrence may be uncertain, enter as G. 34 Wound 4 Protozoa refer to dialysis clearances ONLY (NOT the total of 1500 Oceanian - Polynesian (Specify) 017 Paraproteinaemia (Including Multiple Myeloma) dialysis and renal clearances). 35 Shunt 5 Other 54 - CAUSE OF GRAFT FAILURE 1501 Cook Islander 018 Light Chain Nephropathy (Not Malignant) 36 Peritoneum 1502 Fijian 019 Lithium Toxicity 37 Septicaemia - site unknown (specify organism) 38 CREATININE CLEARANCE (Dialysate only) REJECTION 1503 Niuean 020 Post Partum Nephropathy 38 Liver (incl. viral Hepatitis) (specify A, B, CMV, Range 10-200 litres/week 10 Hyperacute Rejection (within 48 Hrs of Transplantation) 1504 Samoan 021 Sarcoidosis herpes,etc) Litres/week/1.73m² Body Surface Area 20 Acute Rejection at anytime Causing Graft Failure 1505 Tongan 031 Posterior Urethral Valves 39 Other site (specify) 1508 Tokelauan 032 Pelvi-Ureteric Junction Obstruction 39 DIALYSATE WEEKLY Kt/V - Range 0.1 - 5.0 40 Chronic Allograft Nephropathy (Slow Progressive Loss of Function) 2000 North-West European (Specify) 033 Obstructed Megaureter SOCIAL 034 Neuropathic Bladder 40 RESIDUAL RENAL CLEARANCE 3000 Southern and Eastern European (Specify) 40 Withdrawal-Psycho Social Reasons VASCULAR (Creatinine Clearance) 3103 Southern and Eastern European - Italian 035 Non-Obstructed Dilated Bladder (Megacystitis- 41 Patient Refused Treatment (Specify) Litres/week/1.73m² Body Surface Area 3205 Southern and Eastern European - Greek Megaureter) 42 Suicide 50 Renal Artery Stenosis 036 Spina Bifida or Myelomeningocoele 4000 North African and Middle Eastern (Specify) 43 Therapy Ceased Other Reasons (Specify) 51 Renal Artery Thrombosis 037 Bladder Neck Obstruction (incl. Prostatiomegaly) 4100 North African and Middle Eastern - Arab (Specify) 44 Accidental Death (All Causes) Specify 52 Renal Vein Thrombosis 039 Other Lower Urinary Tract Abnormalities (with 49 - SOURCE OF DONOR KIDNEY 4907 North African and Middle Eastern - Turkish 45 Withdrawal-Cardiovascular Comorbid Conditions 53 Haemorrhage (Primary) Secondary Reflux) 100 Deceased 54 Haemorrhage (Secondary) 5000 South-East Asian (Specify) 040 Ureteric Obstructive Nephropathy 46 Withdrawal-Cerebrovascular Comorbid Conditions 200 Sister 55 Embolus - Thrombo 5107 South-East Asian - Vietnamese 041 Obstructive Nephropathy 47 Withdrawal-Peripheral Vascular Comorbid Conditions 201 Brother 56 Embolus - Cholesterol 5201 South-East Asian - Filipino 042 Calcineurin Inhibitor Toxicity 48 Withdrawal-Malignancy 5202 South-East Asian - Indonesian 49 Withdrawal-Dialysis Access Difficulties 202 Mother 57 Haemolytic Uraemic Syndrome 5205 South East Asian - Malay 13 - REASON FOR MODALITY CHANGE 203 Father From CAPD to APD TECHNICAL 6000 North - East Asian (Specify) MISCELLANEOUS 204 Monzygotic (Identical Twin Girl) From APD to CAPD 205 Monzygotic (Identical Twin Boy) 60 Non-Viable Kidney (Due To Pre-Transplant Cortical 6101 North - East Asian - Chinese From any form of PD to HD 50 Hepatic Failure (Specify) 7000 Southern and Central Asian (Specify) 51 Uraemia Caused by Graft Failure 206 Dizygotic (Non-Identical Twin Girl) Necrosis) From HD to any form of PD 61 Cortical Necrosis.
Load more

Recommended publications
  • Guidelines for Contributing Authors
    Charuhas V. Thakar, MD, FASN, FNKF Editor-in-Chief Professor of Medicine Director, Division of Nephrology Kidney C.A.R.E. Program (Clinical Advancement, Research & Education) 231 Albert B Sabin Way Cincinnati, OH 45267 Email: [email protected] Phone: 513-558-5471 Samantha Kramer, Managing Editor Email: [email protected] Guidelines for Contributing Authors Mission Statement The purpose of Advances in Chronic Kidney Disease (ACKD) is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease; the multidisciplinary case management of patients with chronic kidney disease or kidney failure; organ effects of kidney disease; epidemiology and outcomes research in kidney disease; benefits and complications of the primary treatment methods, dialysis and transplantation; technical aspects of the delivery of uremia therapy; care of the critically ill patient with kidney failure in the intensive care setting; new therapies for kidney failure; and health care research in chronic kidney disease. The full spectrum of basic science through clinical care is covered in these reviews. Clinical care issues stress the multidisciplinary team approach to the care of kidney patients. Topics covered will be of interest to practicing nephrologists (pediatric and adult), nephrology fellows (pediatric and adult), nurses, technicians, dieticians, and social workers caring for patients with kidney disease. Each issue of ACKD includes a focused review section of several articles on a topic of current interest.
    [Show full text]
  • Abbreviations
    Abbreviations AAPCC Adjusted average per capita cost CKD-EPI chronic kidney disease epidemiology calculation ACEI angiotensin-converting enzyme inhibitor CKO cytokinin oxidase ACR albumin/creatinine ratio CMS Centers for Medicare & Medicaid Services ADL activities of daily living CMV cytomegalovirus (antibody status) ADR annual data report COPD chronic obstructive pulmonary disease AF atrial fibrillation CORR Canadian Organ Replacement Register AFIB atrial fibrillation CPM clinical performance measures AFS Annual Facility Survey (CMS 2744) CPRA calculated panel reactive bodies AJKD American Journal of Kidney Disease CPT current procedure and terminology AKI acute kidney injury CrCl creatinine clearance rate AKI-D acute kidney injury with dialysis CROWNWeb Consolidated Renal Operations in a Web- AMI acute myocardial infarction Enabled Network (CROWN) Data — data collection system for ESRD dialysis ANZDATA Australia & New Zealand ESRD database facilities mandated by CMS ARB angiotensin receptor blocker CRT cardiac resynchronization ASHD atherosclerotic heart disease CVA cerebrovascular accident AV arteriovenous CVD cardiovascular disease BMI body mass index CVVHD continuous venous-to-venous hemodialysis BUN blood urea nitrogen CWF common working file CABG coronary artery bypass grafting DCD donation after circulatory death CAPD continuous ambulatory peritoneal dialysis DCI Dialysis Clinic, Inc. CBC complete blood count DFC dialysis facility compare CCPD continuous cycling peritoneal dialysis DGF delayed graft function CDC Centers for Disease
    [Show full text]
  • Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate
    الجامعةةةةةةةةةةةةةةةةةةةةة اﻹسةةةةةةةةةةةةةةةةةةةة مية بغةةةةةةةةةةةةةةةةةةةة زة The Islamic University of Gaza عمةةةةةةاحة البحةةةةةةد العلمةةةةةةي والد اسةةةةةةا العليةةةةةةةا Deanship of Research and Graduate Studies كليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة العلةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةو Faculty of Science Master of Biological Sciences ماجسةةةةةةةةةةةةةةةةةةتير العلةةةةةةةةةةةةةةةةةةو الحياتيةةةةةةةةةةةةةةةةةةةة Medical Technology التحةةاليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةل الطبيةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى مرضى الفشل الكلوي المزمن في مستشفى الشفاء - محافظة غزة Prepared By Fawwaz H. Eliglah Supervisor Prof. Baker M. Zabut Faculty of Science Biochemistry Department The Islamic University of Gaza A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biological Sciences- Medical Technology September , 2018 إقةةةةةةةةةةةةةةرا أنا الموقع أحناه مقد الرسالة التي تحمل العنوان: Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى ي مرضى الفشل الكلو المزمن في مستشفى الشفاء - محافظة غزة أقر بأن ما اشتملت عليه هذه الرسالة إنما هو نتاج جهدي الخاص، باستثناء ما تمت اﻹشارة إليه حيثما ورد، وأن هذه الرسالة ككل أو أي جزء منها لم يقدم من قبل اﻻخرين لنيل درجة أو لقب علمي أو بحثي لدى أي مؤسسة تعليمية أو بحثية أخرى. Declaration I understand the nature of plagiarism, and I am aware of the University’s policy on this. The work provided in this thesis, unless otherwise referenced, is the researcher's own work, and has not been submitted by others elsewhere for any other degree or qualification. اسم الطالب: فواز حسن العجلة :Student's name التوقيع: Signature: Fawwaz H.
    [Show full text]
  • Manual of Clinical Dialysis
    Manual of Clinical Dialysis Second Edition Manual of Clinical Dialysis Second Edition Suhail Ahmad University of Washington, Scribner Kidney Center, Northwest Kidney Centers, Seattle, Washington, USA ABC Suhail Ahmad, MD Professor, Medicine University of Washington Scribner Kidney Center Northwest Kidney Centers Seattle, Washington [email protected] ISBN: 978-0-387-09650-6 e-ISBN: 978-0-387-09651-3 DOI: 10.1007/978-0-387-09651-3 Library of Congress Control Number: 2008928866 °c Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com Grateful thanks to my family, Vimli, Saba, and Zeba, and friends for their strong support and to Arlene for all of her help.
    [Show full text]
  • Kt/V Calculations for the Assessment of Hemodialysis Adequacy
    Wt 0.10 0.08 0.06 0.04 1.80 0.02 0.00 1.60 1.40 Kt/V 1.20 1.00 0.80 0.60 0.40 0.50 0.60 0.70 0.80 URR We have found that the Keshaviah Quick Kt/V formula most closely correlates with both of the more complex Kt/V calculations that Spectra offers - the Daugirdas II Natural Log and Depner Full UKM Kt/V (see Figures 2 & 3). Comparison of Kt/V Formulas to UKM Kt/V Comparison of Kt/V Formulas to UKM Kt/V 1500 Patient Results 0.6 to 2.0 2.20 2.20 2.00 2.00 1.80 1.80 1.60 1.60 1.40 1.40 1.20 Kt/V Calculations for 1.00 1.20 0.80 1.00 0.60 the Assessment of 0.40 1 4 7 0.80 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 101 103 105 107 109 111 113 115 117 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 97 112 115 118 100 103 106 109 121 Hemodialysis Adequacy Depner Full UKM Depner Full UKM Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Jindal 0.04*URR-1.2 Jindal 0.04*URR-1.2 Basile 0.023*URR-0.284 Basile 0.023*URR-0.284 Depner 0.026*URR-0.49 Depner 0.026*URR-0.49 Keshaviah 1.162*In(Pre/Pst) Keshaviah 1.162*In(Pre/Pst) Figure 2 Figure 3 References 1 Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error.
    [Show full text]
  • Increasing Blood Flow Rate; a Tool to Improve Adequacy of Dialysis
    ORIGINAL ARTICLE ISRA MEDICAL JOURNAL | Volume 9 - Issue 6 | Nov - Dec 2017 Increasing Blood Flow Rate; A Tool To Improve Adequacy Of Dialysis Aurangzeb Afzal1, Maira Iqbal Malik2, Adnan Shabbir2 ABSTRACT OBJECTIVE: To assess the effect of increasing blood flow rate on the adequacy of dialysis, and to prove that increased blood flow can be helpful in achieving adequate dose of dialysis, in patients having low efficiency of dialysis . STUDY DESIGN: Quasi experimental study PLACE AND DURATION: At Dialysis unit of Lahore General Hospital over a period of 1 month from 28th January to 28th February 2017. METHODOLOGY: A total of 40 patients on regular hemodialysis participated in this study. Hemodialysis was performed at two different blood flow speeds 300 and 350 ml/min. Blood samples were obtained just before start and 45 minutes after completion of dialysis to measure urea levels. Urea Reduction Ratio (URR) was used as an index of dialysis dose and hence dialysis efficiency. RESULT: Increasing blood flow rate from 300 to 350ml/min has a significant impact on URR and hence on dialysis adequacy. It was observed that increasing blood flow rate from 300ml/min to 350ml/min raised URR from 53% to 60%. Marked statistical difference in URR between the two groups that is 7% was observed using the paired T-test. P value was 0.001 (<0.05). CONCLUSION: Increasing blood flow rate (BFR) has been successful in boosting effective dose of dialysis and is likely to prove beneficial for patients requiring hemodialysis. KEYWORDS: Hemodialysis, Adequacy, Blood Flow Rates, Low Efficiency, Urea reduction ratio.
    [Show full text]
  • Urea Reduction Ratio (URR) for Dialysis
    Urea Reduction Ratio or URR How do I know I am getting the right amount of dialysis? The correct amount of dialysis to clear waste products from your body is called dialysis adequacy. The health care team uses many ways to find out if you are having adequate dialysis. How should I feel? When your dialysis therapy is adequate, you should have more energy. You should also sleep better and feel like eating. When your dialysis therapy needs adjusting, you may feel weak and tired. You may not sleep well. You may not feel like eating or may have an upset stomach. You may also have some swelling in the ankles or feet or have problems breathing. What is URR? One way to assess dialysis adequacy is to do a blood test called Urea Reduction Ratio or URR. This test measures a waste product called urea. A blood sample is taken before and after the dialysis treatment through the dialysis machine. The laboratory then tests the blood for urea. The results come back as a percentage of urea lowered during the dialysis treatment. The Dialysis Units do URR blood tests once a month on all dialysis patients. Your dialysis therapy will aim to give you a URR of 65% or more - the higher the number the better. This means the hemodialysis treatments are working well to get rid of waste products in your body. If your blood test result is below 65%, the doctor will assess your dialysis prescription and improve your URR. Each person will have a number that the doctor feels is right for that person.
    [Show full text]
  • Factors That Affect Postdialysis Rebound in Serum Urea Concentration, Including the Rate of Dialysis: Results from the HEMO Study
    J Am Soc Nephrol 15: 194–203, 2004 Factors that Affect Postdialysis Rebound in Serum Urea Concentration, Including the Rate of Dialysis: Results from the HEMO Study JOHN T. DAUGIRDAS, TOM GREENE, THOMAS A. DEPNER, JOHN LEYPOLDT, FRANK GOTCH, GERALD SCHULMAN, and ROBERT STAR for the Hemodialysis (HEMO) Study Group National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland Abstract. Previous studies have suggested that postdialysis was the strongest predictor of rebound among 22 factors con- urea rebound is related to K/V, the rate of dialysis, but a sidered. Other factors associated with greater rebound for 1331 systematic analysis of factors that affect rebound has not been patients using AV accesses or venous catheters included access reported. With the use of 30-min and, in a subset, 60-min type, black race, male gender, absence of congestive heart postdialysis samples, postdialysis urea rebound was measured failure, greater age, ultrafiltration rate, and low predialysis or to (1) determine how well previously proposed equations based intradialysis systolic BP. Equations of the form eKt/V ϭ on the rate of dialysis (K/V) predict rebound in a large sample single-pool Kt/V Ϫ B ϫ (K/V) were fit to the data. With AV of patients with varying characteristics, (2) determine whether access, the optimum values for the slope term (B) were 0.39 other factors besides K/V affect rebound, and (3) estimate and 0.46 (in hϪ1) for single-pool Kt/V calculated based on 20-s more precise values for coefficients in prediction equations for postdialysis or immediate postdialysis samples, respectively.
    [Show full text]
  • Hemodialysis Dose and Adequacy
    Hemodialysis Dose and Adequacy When kidneys fail, dialysis is neces­ The amount of urea removed (35 mg/dL) sary to remove waste products such as is expressed as a percentage of the pre- urea from the blood. By itself, urea is dialysis urea level (50 mg/dL). only mildly toxic, but a high urea level 35/50 = 70/100 = 70% means that the levels of many other waste products that are more harm­ Although no fixed percentage can be ful and not as easily measured are also said to represent an adequate dialysis, building up. patients generally live longer and have fewer hospitalizations if the URR is To see whether dialysis is removing at least 60 percent. As a result, some enough urea, the dialysis clinic should experts recommend a minimum URR periodically—normally once a month— of 65 percent. test a patient’s blood to measure dialysis adequacy. Blood is sampled at the start The URR is usually measured only once of dialysis and at the end. The levels of every 12 to 14 treatments, which is urea in the two blood samples are then once a month. The URR may vary con­ compared. Two methods are generally siderably from treatment to treatment. used to assess dialysis adequacy, URR Therefore, a single value below 65 per­ and Kt/V. cent should not be of great concern, but a patient’s average URR should exceed What is the URR? 65 percent. URR stands for urea reduction ratio, meaning the reduction in urea as a What is the Kt/V? result of dialysis.
    [Show full text]
  • Urea Reduction Ratio May Be a Simpler Approach for Measurement of Adequacy of Intermittent Hemodialysis in Acute Kidney Injury Kelly V
    Liang et al. BMC Nephrology (2019) 20:82 https://doi.org/10.1186/s12882-019-1272-7 RESEARCHARTICLE Open Access Urea reduction ratio may be a simpler approach for measurement of adequacy of intermittent hemodialysis in acute kidney injury Kelly V. Liang1* , Jane H. Zhang2 and Paul M. Palevsky3 Abstract Background: Assessment of adequacy of intermittent hemodialysis (IHD) is conventionally based upon urea kinetic models for calculation of single pool Kt/Vurea (Kt/V), with 1.2 accepted as minimum adequate clearance for thrice weekly IHD. In the Acute Renal Failure Trial Network (ATN) Study, adequacy of IHD in patients with acute kidney injury (AKI) was assessed using Kt/V. However, equations for Kt/V require volume of distribution of urea, which is highly variable in AKI. Therefore, simpler methods are needed to assess adequacy of IHD in AKI. We assessed correlation of urea reduction ratio (URR) with Kt/V and determined URR thresholds corresponding to Kt/V values to determine if URR could be a simpler means to assess the delivered dose of IHD. Methods: Using patients who received IHD for 2.5–6 h and with pre-dialysis BUN ≥20 mg/dL, we plotted URR against Kt/V. We determined URR thresholds (0.60 to 0.75) corresponding to Kt/V ≥ 1.2, 1.3, and 1.4. We generated receiver operating characteristic (ROC) curves for increasing URR values for each level of Kt/V to identify the corresponding thresholds of URR. Results: There was strong correlation between URR and Kt/V. ROC curves comparing URR with Kt/V ≥ 1.2, 1.3, and 1.4 had area under the curves (AUC) of 0.99.
    [Show full text]
  • Nkf-Doqi Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
    NKF-DOQI CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY 867 Acronyms and Abbreviations Abbreviation Term ACE angiotensin-converting enzyme BSA body surface area BUN blood urea nitrogen concentration (an old term; SUN is technically correct, see below) CANUSA Canada/USA Peritoneal Dialysis Study CAPD continuous ambulatory peritoneal dialysis CCPD continuous cycling peritoneal dialysis CCr creatinine clearance CrCr residual renal creatinine clearance DI dialysis index DPI dietary protein intake eC effective clearance ESRD end-stage renal disease GFR glomerular filtration rate HD hemodialysis Kpcr peritoneal creatinine clearance KptlVurea the peritoneal component of KtIV urea KprtlVurea the sum of peritoneal and renal KtIV urea. These terms are interchangeable in that KtIVurea is total unless otherwise noted. KtlVurea urea clearance X time normalized by total body water, the volume of distribution of urea KrtlVurea the renal component of KtIV urea MTC mass transfer coefficient n normalized nBSA normalized body surface area NIPD nightly intermittent peritoneal dialysis nPCR normalized protein catabolic rate nPNA normalized protein equivalent of total nitrogen appearance nV normalized volume PCR protein catabolic rate PD peritoneal dialysis PET peritoneal equilibration test PNA protein equivalent of nitrogen appearance QOL quality of life RRF residual renal function SGA subjective global assessment SHR standardized hospitalization rates SUN serum urea nitrogen concentration t time UKM urea kinetic modeling UNA urea nitrogen appearance URR urea reduction ratio USRDS United States Renal Data System V volume of distribution. When referring to urea, this is total body water S68 Introduction This Work Group was charged with preparing purpose of these guidelines, a child was considered practice guidelines for the "adequacy of perito• to be a' patient less than 19 years of age.
    [Show full text]
  • (ESRD) Quality Measure Development and Maintenance Hemodialysis Adequacy Clinical Technical Expert Pane
    End Stage Renal Disease (ESRD) Quality Measure Development and Maintenance Hemodialysis Adequacy Clinical Technical Expert Panel Summary Report Prepared by: Arbor Research Collaborative for Health and the University of Michigan Kidney Epidemiology and Cost Center Conducted April 16-17, 2013 in Baltimore, MD Sent to CMS on June 28, 2013 Contract No. 500-2008-00022I, Task Order No. HHSM-500-T0001 1 Table of Contents Technical Expert Panel Summary .................................................................................................................. 5 1. Introduction/Background: ........................................................................................................................ 7 2. Discussion of Urea Kinetics ....................................................................................................................... 8 2.1 Standardized (Std) Kt/V ....................................................................................................................... 9 2.1.1 Literature Review & Scientific Importance .................................................................................. 9 2.1.2 Scientific acceptability: .............................................................................................................. 10 2.1.3 Feasibility and usability: ............................................................................................................. 10 2.1.4 Review of existing measures: ....................................................................................................
    [Show full text]